Haleon Reports Preliminary 2025 Full Year Results and Proposes 7.1p Dividend

Free cash flow and organic profit growth: what was actually said

Haleon points to the strength of free cash flow (FCF) and strong organic operating profit growth as the rationale for the dividend. Free cash flow is the cash left after operating expenses and capital expenditure, the fuel for dividends and debt reduction. Organic operating profit growth refers to profit growth from the existing business, excluding items like acquisitions, disposals or currency effects.

Numbers for revenue, margins, cash flow and guidance are not disclosed in this RNS. They will be in the full preliminary statement. The tone is constructive though: you do not raise or maintain a healthy payout ratio unless you believe cash generation is robust.

Earnings cover and dividend sustainability

A 38% payout ratio implies earnings cover of roughly 2.6x. In plain English, profits comfortably cover the dividend while leaving room for reinvestment. That balance tends to be supportive for long-term dividend sustainability.

It is also notable that policy guidance remains conservative: grow the dividend at least in line with adjusted earnings. There is no promise of outsized increases, but there is a clear link to performance, which investors can test against future results.

Where to find the full results and how to join the Q&A

The full preliminary results statement for the year ended 31 December 2025 is available here: RNS PDF. It will also be hosted on the company’s site: haleon.com/investors, and on the FCA’s National Storage Mechanism: NSM.

A recorded results presentation by CEO Brian McNamara and CFO Dawn Allen will be available shortly after 7:00am GMT on 25 February 2026. The live Q&A starts at 8:45am GMT, with these dial-in details:

• UK: +44 (0) 808 189 0158
• US: +1 855 979 6654
• All other: +44 (0) 203 936 2999
• Passcode: 049869

An archived webcast of the Q&A will be available later in the day on the investor site.

What could move the share price when investors digest the full statement

Given this announcement focuses on availability rather than detail, the market will likely home in on the full document for the specifics. Key swing factors typically include:

• Adjusted earnings growth and margin trends, to back up the payout policy.
• Free cash flow conversion and any working capital commentary.
• Outlook language for 2026, especially around organic growth and cost inflation.
• Any updates on capital allocation beyond dividends.

Because Haleon sells across categories like Oral Health, VMS and Pain Relief, category growth and brand performance often set the tone for guidance. The press release does not disclose these details.

Quick take: positives and watch-outs

Reasons to be upbeat

• Proposed 7.1p total dividend with a disciplined 38% payout ratio.
• Management cites strong free cash flow and organic operating profit growth.
• Policy to grow the dividend at least in line with adjusted earnings provides a clear framework.

Things to watch

• Financial specifics are not disclosed in this RNS. Investors need the full statement for the numbers.
• The final dividend is subject to shareholder approval.
• Different ex-dividend dates for ordinary shares and ADS holders, so timing matters.

Haleon at a glance

Haleon is a global consumer health player with brands like Advil, Centrum, Otrivin, Panadol, parodontax, Polident, Sensodyne, Theraflu and Voltaren. The portfolio spans Oral Health, Vitamins, Minerals and Supplements, Pain Relief, Respiratory Health, Digestive Health and Therapeutic Skin Health and Other. The company pitches itself on trusted science and innovation to drive everyday health products.

Bottom line

This is a clean, shareholder-friendly update. A 7.1p total dividend and a steady 38% payout ratio suggest confidence without overreach. The real test will be the detail in the full preliminary results and the tone of the Q&A, but on the headline read-through, cash generation looks supportive and the dividend policy remains sensible.